MarketInOut Stock Screener Log In | Sign Up
 

Protalix BioTherapeutics Inc

NYSE • Healthcare • Biotechnology • Quote as of 10/23/2026
Protalix BioTherapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization205.05 mln
Float77.45 mln
Earnings Date11/16/2026

EPS

0.23
Marginal

P / E

11.09
Fair value

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

-1.57
Likely manipulated

Relative Strength

13 / 100
Significantly lagging

Debt / Equity

0.13
Very low leverage

Business Description

Protalix BioTherapeutics is a New Jersey-based company that develops and sells medical treatments derived from plant cells. Its current products address Gaucher disease and Fabry disease, while additional treatments for gout and certain immune-related conditions are progressing through clinical trials. The company works alongside several global partners, including Pfizer and Chiesi Farmaceutici, to advance and distribute its therapies.

Key Fundamentals

EPS0.23
P/E11.09
ROE32.70
RPS1.01
ROIC52.91
ROA20.78
Interest Cover18.63
EBITDA, mln26.28
EV / EBITDA7.41
EV / EBIT7.88
Revenue, mln80.62
EV / Revenue2.42

Quote Details

Last 2.55
Change -0.02 (-0.78%)
Open 2.54
Volume 383,906
Turnover 978,960
Average Volume 900,912

Financial Ratios

Pre-Tax Profit Margin29
Leverage Ratio1.55
Current Ratio2.94
Price / Book3.10
Price / Tangible Book3.10
Price / Cash Flow20.51
Price / Free Cash Flow30.31
Debt / Equity0.13
Price / Sales2.83

Financial Strength

Altman Z-Score0.87
Piotroski F-Score 6 / 9
Beneish M-Score-1.57
Price to Graham Number1.30
Short Ratio4.16
Short % of Float3.93

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -2.67% 16 / 100   
1 Month -7.27% 18 / 100   
2 Months 5.81% 83 / 100   
6 Months 16.97% 89 / 100   
1 Year 12.33% 62 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog